1/15 Late treatment study
, The Lancet, doi:10.1016/S0140-6736(21)00897-7 (press release 1/15/2021) (Peer Reviewed)
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
RCT 16,287 hospitalized patients in the UK, showing no significant differences with convalescent plasma treatment. Subgroup analysis shows better results for those treated <= 7 days from symptom onset. NCT04381936.
Recovery Collaborative Group et al., 1/15/2021, Randomized Controlled Trial, United Kingdom, Europe, peer-reviewed, 1 author.
risk of death, no change, RR 1.00, p = 0.95, treatment 1399 of 5795 (24.1%), control 1408 of 5763 (24.4%), day 28.
risk of no hospital discharge, 1.0% higher, RR 1.01, p = 0.57, treatment 1963 of 5795 (33.9%), control 1941 of 5763 (33.7%), day 28.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.